Tirofiban (hydrochloride monohydrate)

Tirofiban (hydrochloride monohydrate)

• CAS Number: 150915-40-5
• UNSPSC Description: Tirofiban (L700462) hydrochloride monohydrate is a selective and reversible platelet integrin receptor (Gp IIb/IIIa) antagonist that inhibits fibrinogen binding to this receptor and has antithrombotic activity. Tirofiban hydrochloride monohydrate induces proliferation and migration on endothelial cell by inducing production of VEGF. Tirofiban hydrochloride monohydrate can significantly reduces myocardial no-reflow and ischemia-reperfusion injury by alleviating myocardial microvascular structural and endothelial dysfunction in the ischemic area[1][2][3].
• Target Antigen: Integrin
• Type: Reference compound
• Related Pathways: Cytoskeleton
• Applications: COVID-19-immunoregulation
• Field of Research: Cardiovascular Disease
• Assay Protocol: https://www.medchemexpress.com/Tirofiban-hydrochloride-monohydrate.html
• Solubility: DMSO : 100 mg/mL (ultrasonic)
• Smiles: O=S(N[C@H](C(O)=O)CC1=CC=C(OCCCCC2CCNCC2)C=C1)(CCCC)=O.[H]Cl.[H]O[H]
• Molecular Weight: 495.07
• References & Citations: [1]Giordano A, et al. Tirofiban induces VEGF production and stimulates migration and proliferation of endothelial cells. Vascul Pharmacol. 2014 May-Jun;61(2-3):63-71.|[2]Liu X, et al. Effects of tirofiban on the reperfusion-related no-reflow in rats with acute myocardial infarction. J Geriatr Cardiol. 2013 Mar;10(1):52-8.|[3]Yates YJ, et al. The effect of tirofiban on microvascular thrombosis: crush model. Plast Reconstr Surg. 2005 Jul;116(1):205-8
• Shipping Conditions: Room Temperature
• Clinical Information: Launched